Investors

Home / Investors / Press Releases

CymaBay Therapeutics to Participate in Upcoming Investor Conferences in March

Download PDF

NEWARK, Calif., March 05, 2018 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management will participate in upcoming investor conferences, including the 30th Annual ROTH Conference, the H.C. Wainwright 2nd Annual NASH Investor Event, and the Oppenheimer & Company 28th Annual Healthcare Conference.

30th Annual ROTH Conference 2018
Date:                    Monday, March 12
Time:                    9am Pacific Time
Location:              Ritz Carlton, Laguna Niguel, CA

H.C. Wainwright 2nd Annual NASH Investor Event
Date:                    Monday, March 19
Time:                    9:20am Eastern Time
Location:              St. Regis Hotel, New York, NY
Webcast:             http://ir.cymabay.com/events

Oppenheimer & Company 28th Annual Healthcare Conference
Date:                    Tuesday, March 20
Time:                    9:10am Eastern Time
Location:              Westin New York Grand Hotel, NY
Webcast:             http://ir.cymabay.com/events

About CymaBay
CymaBay Therapeutics, Inc. (CBAY) is a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need. Seladelpar is a potent, selective, orally active PPARδ agonist currently in development for the treatment of patients with primary biliary cholangitis (PBC), an autoimmune liver disease, and with nonalcoholic steatohepatitis (NASH). Two Phase 2 studies of seladelpar established proof of concept in PBC. CymaBay is currently planning to advance development of seladelpar into Phase 3 for PBC and Phase 2 for NASH.

For additional information about CymaBay visit www.cymabay.com.

Contact:              
Hans Vitzthum
LifeSci Advisors, LLC
212-915-2568
Hans@LifeSciAdvisors.com

Primary Logo

Source: CymaBay Therapeutics, Inc.